Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 20:17:100634.
doi: 10.1016/j.ajpc.2024.100634. eCollection 2024 Mar.

Trends in prevalence, risk factor control and medications in atherosclerotic cardiovascular disease among US Adults, 1999-2018

Xiaowen Zhang  1   2 , Zheng Chen  3 , Aijuan Fang  4 , Lina Kang  3 , Wei Xu  3 , Biao Xu  3 , Jianzhou Chen  3 , Xinlin Zhang  3
Affiliations

Trends in prevalence, risk factor control and medications in atherosclerotic cardiovascular disease among US Adults, 1999-2018

Xiaowen Zhang et al. Am J Prev Cardiol. .

Abstract

Objectives: Trends in prevalence and treatments of atherosclerotic cardiovascular disease (ASCVD) remains to be documented, with frequent update of relevant guidelines. We aimed to characterize trends in prevalence of ASCVD, and risk factor control and medications among ASCVD adults.

Methods: We conducted a cross-sectional analysis of data from 55,081 adults in the National Health and Nutrition Examination Surveys (NHANES) 1999-2018.

Results: The age-standardized prevalence of ASCVD did not change significantly from 1999-2002 (7.9 %, 95 % CI 7.1 %-8.7 %) to 2015-2018 (7.5 %, CI 6.8 %-8.3 %) (P for trend =0.18), representing an estimated 19.9 million individuals with ASCVD in 2015-2018. The prevalence of premature ASCVD was 2.0 % (CI, 1.6 %-2.5 %). Over 60.0 % of ASCVD participants were at very-high risk. From 1999-2002 to 2015-2018, the percentage with lipid control (non-high-density lipoprotein cholesterol <100 mg/dL) increased from 7.0 % (CI, 3.5 %-12.3 %) to 26.4 % (CI, 16.2 %-38.9 %). The percentage with blood-pressure control (<130/80 mmHg) increased from 51.2 % (CI, 41.0 %-61.3 %) in 1999-2002 to 57.2 % (CI, 48.4 %-65.6 %) in 2011-2014, but then declined to 52.8 % (CI, 44.4 %-81.3 %) in 2015-2018. The percentage with glycemic control (HbA1c <7.0 %) decreased from 95.0 % (CI, 90.2 %-97.9 %) to 84.0 % (CI, 75.9 %-90.3 %). The percentage who achieved all 3 targets was 18.6 % (CI, 8.2 %-33.8 %) in 2015-2018. The percentage of ASCVD participants who were taking statins increased from 1999-2002 to 2011-2014, but then leveled off. Approximately 60 % of individuals with ASCVD and less than 40 % of those with premature ASCVD were taking statins in 2015-2018. The utilization of blood-pressure-lowering drugs remained largely constant over time, whereas the use of glucose-lowering drugs increased.

Conclusions: Based on NHANES data from US adults, the estimated prevalence of ASCVD remained relatively stable between 1999 and 2018. Substantial undertreatment with stains was found in individuals with ASCVD, and the percentage achieving optimal lipid control was low.

Keywords: blood pressure; glucose; lipid; medications; prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Unlabelled image
Central Illustration. Prevalence of ASCVD, risk factor control and medications among US adults, 1999–2002 to 2015–2018. The age-standardized prevalence of ASCVD was 7.5 % in 2015–2018, with the prevalence of coronary heart disease (CHD) doubles that of stroke. Among ASCVD adults, 61.0 % were at very-high risk. Blood-pressure, lipid, and glycemic control was achieved in 52.8 %, 26.4 % and 84 % of participants respectively, and 18.6 % of ASCVD participants achieved control of all 3 risk factors in 2015–2018. Trends in medications among US adults with ASCVD and premature ASCVD, 1999–2002 to 2015–2018, showing a lower percentage of medications in participants with premature ASCVD.
Fig 1
Fig. 1
Trends in prevalence of ASCVD among US adults, 1999–2002 to 2015–2018. ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease.
Fig 2
Fig. 2
Trends in risk factor control among US adults with ASCVD, 1999–2002 to 2015–2018. ASCVD, atherosclerotic cardiovascular disease.
Fig 3
Fig. 3
Trends in medications among US adults with ASCVD, 1999–2002 to 2015–2018. (A) Lipid-lowering medications. (B) Blood-pressure-lowering medications. (C) Glucose-lowering medications. ASCVD, atherosclerotic cardiovascular disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tsao C.W., Aday A.W., Almarzooq Z.I., et al. Heart disease and stroke statistics-2022 update: a report from the American heart association. Circulation. 2022;145:e153–e639. - PubMed
    1. Rosinger A., Carroll M.D., Lacher D., Ogden C. Trends in total cholesterol, triglycerides, and low-density lipoprotein in US adults, 1999-2014. JAMA Cardiol. 2017;2:339–341. - PMC - PubMed
    1. Ogden C.L., Fryar C.D., Martin C.B., et al. Trends in obesity prevalence by race and Hispanic origin-1999-2000 to 2017-2018. JAMA. 2020;324:1208–1210. - PMC - PubMed
    1. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129:S1–45. - PubMed
    1. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2018;138:e426–ee83. - PubMed

LinkOut - more resources